The story behind Transino Read the full story

Consider how rarely a beauty product carries a package insert. Tucked inside every box is a folded sheet of warnings, dosing schedules, and contraindications that reads like medication paperwork because, regulatorily, that is precisely what it is. The flagship is taken by mouth, not smoothed on: a tablet course intended to run for a defined stretch of weeks rather than indefinitely, with explicit guidance to stop after a set period and reassess. That oral-first logic is the brand's defining oddity. Rather than treating discoloration purely at the skin's surface, the original concept aims at the biological signal upstream. The reasoning traces to how the patches form: a messenger compound, plasmin, prods pigment-producing cells into overactivity, and the active is thought to quiet that prompt before extra pigment is ever manufactured. To support the mechanism, the tablets pair the lead active with L-cysteine and vitamin C, nutrients chosen to assist the same pigment-management pathway from inside the body. Commercial traction came almost embarrassingly fast, with reported sales climbing into the billions of yen within roughly the first half-year, a sign that shoppers exhausted by vague luminosity promises responded to something framed as treatment. The portfolio later branched into topical companions, including medicated essences, lotions, sticks for spot application, and richer creams, letting a routine attack the same target from surface and system at once. Two cautions stay paramount. The oral active is a real pharmaceutical with genuine restrictions, unsuitable for certain people and not a casual daily supplement, and everything is formulated and labeled for the Japanese domestic market, where the relevant 'quasi-drug' and OTC categories differ from regulations abroad. Discoloration also tends to creep back without disciplined daily sun protection, so patience and consistency matter as much as the formula. Within its narrow specialty, this remains an unusually disciplined offering, structured like medicine because it behaves like it.

Sources:[1][2][3]

Founded
2007
Origin
Japan
Parent company
Daiichi Sankyo Healthcare
Heritage
Established
Type
Pharmacy brand
Verdicts
0 Strong choice · 0 Good choice of 3 assessed
3 products reviewed

All Transino Products

Promising hyperpigmentation
No.1
Transino Whitening Clear Lotion Japanese pharmacy tranexamic acid toner 175ml Japanese Pharmacy Whitening Specialist
Transino toner

Whitening Clear Lotion

The flagship toner from Daiichi Sankyo's specialty bihaku line — purpose-built around tranexamic acid as the central active for melasma and post-inflammatory hyperpigmentation. Quasi-drug certified, gently formulated for sensitive aging skin, and backed by Daiichi Sankyo's pharmaceutical research depth. Earns its place as one of the most-recommended Japanese pharmacy whitening toners for users seriously committed to gradual pigmentation correction.

Key Tranexamic Acid · Probiotics & Prebiotics

normalcombination Fragrance Free
4.4 (4.2k)
$38.00 $6.42/fl oz
Promising hyperpigmentation
No.2
Transino Whitening Clear Milk Japanese pharmacy bihaku emulsion 100ml Japanese Pharmacy Bihaku Emulsion
Transino moisturizer

Whitening Clear Milk

The emulsion step in Daiichi Sankyo's specialty bihaku routine — dual quasi-drug actives, multi-botanical brightening layer, and CHD penetration enhancement in a lightweight Japanese milk format. Earns its premium pricing through formulation depth and the Transino brand specialization. Best used alongside the Transino Whitening Clear Lotion for the layered approach the brand was designed around.

Key Tranexamic Acid · Botanical Extracts

normalcombination Fragrance Free
4.4 (2.7k)
$42.00 $12.42/fl oz
Promising hyperpigmentation
No.3
Transino Whitening Repair Cream EX Japanese pharmacy melasma night cream 35g Japanese Pharmacy Bihaku Night Cream
Transino moisturizer

Whitening Repair Cream EX

The most concentrated treatment product in Daiichi Sankyo's specialty bihaku line — dual quasi-drug actives, multi-botanical brightening complex (5 botanicals), ectoine for environmental defense, and occlusive night-cream architecture for maximized active contact. Earns its premium pricing for the formulation depth and depth specialization. Best for serious melasma users committed to the full Transino routine.

Key Tranexamic Acid · Botanical Extracts

drynormal Fragrance Free
4.4 (2.2k)
$65.00 $52.65/oz

More about Transino

Launched in 2007 by Daiichi Sankyo Healthcare as Japan's first OTC drug approved to treat melasma, built on tranexamic acid (an active well-supported in dermatological literature for melasma); the broader medicated skincare line followed in 2014.